 Cyclerion Therapeutics Incs NASDAQ: CYCN preclinical studies demonstrated its lead soluble guanylate cyclase sGC stimulator, CY6463, improved cellular energetics and reduced inflammation in preclinical models of mitochondrial disease. The data will be presented at the. 